We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections

By LabMedica International staff writers
Posted on 23 Feb 2024

Annually, a staggering half a million people, including numerous children and young individuals, succumb to serious infections caused by the group A streptococcal (Strep A) bacteria globally. More...

Strep A is highly transmissible and spreads from person to person mostly via the respiratory route from sore throats. Strep A is typically known for causing sore throats and skin infections in younger children.  In rare cases, it can lead to more severe conditions like sepsis and toxic shock if the bacteria invade the bloodstream or tissue. While adults are often immune to Strep A sore throats and skin infections, both adults and children are very susceptible to the invasive form of the infection. A particularly alarming consequence of repeated Strep A infections is the autoimmune-induced damage to heart valves, termed rheumatic heart disease (RHD). RHD affects approximately 50 million people worldwide, predominantly in middle- and low-income countries. Currently, there is no vaccine available for Strep A. The development of immunity to Strep A over time, including the identification of specific bacterial antigens crucial for targeting by the immune system or future vaccines, remains poorly understood. Additionally, the distinction between detrimental immune overreactions to Strep A, leading to RHD, and the desirable protective immunity is not clearly defined.

In response to this global health challenge, an international collaboration of scientists has established a comprehensive network to investigate the bacterial causes of sepsis and heart damage caused by Strep A. The iSpy Network (immunity to Streptococcus pyogenes), led by Imperial College London (London, UK), along with the University of California San Diego (La Jolla, CA, USA), unites 28 researchers from 11 countries. This diverse group of experts in immunology, infectious disease, epidemiology, vaccinology, and experimental medicine will engage in a five-year project. Their goal is to utilize a broad spectrum of advanced techniques to delve into Strep A immunity with unprecedented detail, ultimately contributing significantly to reducing the global impact of Strep A.

The iSpy-LIFE sub-network aims to uncover how effective immunity to Strep A develops in children, following natural infection over time. This research, involving young children, school-age pupils, and adults, may provide insights into genuine immunity against Strep A and guide the development of a vaccine that mimics and accelerates this immunity in children. Additionally, the iSpy-EXPLORE sub-network is set to explore the nature of protective immune responses in experimental models exposed to promising Strep A vaccine candidates. It will also assess human immune responses in healthy volunteers experimentally exposed to Strep A infections. Collectively, these efforts are poised to enhance understanding of both beneficial and detrimental immunity to Strep A, paving the way for a future vaccine that could protect against strep throat, invasive infections, and RHD.

“The RHD patients we see in LMICs generally present with advanced disease and complications such as heart failure,” said Professor Liesl Zuhlke, a pediatric cardiologist at The University of Cape Town and iSpy team member. “Many require cardiac surgery or percutaneous intervention which are often not available, resulting in significant mortality and morbidity and incurring huge out-of-pocket costs to families and communities. We desperately need data on transitions between the various forms of Strep A diseases and how we can intervene to prevent these manifestations.”

Related Links:
Imperial College London
University of California San Diego 


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Microbiology

view channel
Image: Graphical Abstract (Emery, J. K., V. Nemidkanam, N. Colon, et al. Journal of Extracellular Vesicles (2026). https://doi.org/10.1002/jev2.70286)

Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori

Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.